The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
Purpose
As a result of the COVID-19 pandemic, the Therapeutic Goods Administration (TGA) is receiving an increased number of enquiries from people seeking to develop medical devices or component parts of medical devices including using 3D printing or other advanced manufacturing technology.
The following guidance aims to assist manufacturers of medical devices and their component parts with meeting their regulatory obligations.